FDA: 5-Alpha-Reductase Inhibitors May Increase High-Grade Prostate Cancer Risk

There is a constant debate between both oncologist and advocates about the value and safety of 5-alpha-reductase inhibitors (Proscar and Avodart) both in the early treatment and later treatment of men with prostate cancer. In fact, I have had an on-going private debate with one very knowledgeable educator advocate over this issue. I often have [...]

Does ADT3 Work for Men with A Biochemical Prostate Cancer Recurrence?

One of the most heated debates in prostate cancer care is around the use of 5-reductase inhibitors (5ARI) like Dutasteride as a third component of a hormone blockade (ADT3). 5-ARIs block the conversion of testosterone to dihydrotestosterone (DHT). DHT is thought to be an extremely powerful “fuel” for the growth of prostate cancer. However, there [...]

Dutasteride (Avodart) Provides No Clinical Benefit to Men with Recurrent Castrate Resistant Prostate Cancer

At the University of New Mexico School of Medicine in Albuquerque, New Mexico (SKS) the Department of Urology just completed a study that showed that dutasteride, the generic name for a dual 5alpha-reductase inhibitor made by GlaxoSmithKline and marketed under the name Avodart™ in the US and Avolve™ in Europe, when administered to men with [...]